Trials / Recruiting
RecruitingNCT06533644
A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer
A Phase 2a Multicenter, Dose-Escalation and Dose Optimization Study of SYNC-T Therapy SV-102 for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- Sponsor
- Syncromune, Inc. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MTD) and/or selected dose for phase 2b study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Partial Oncolysis | Partial tumor oncolysis will be completed by cryolysis. |
| DRUG | SV-102 | Intratumoral infusion of SV-102 |
Timeline
- Start date
- 2025-05-29
- Primary completion
- 2027-12-14
- Completion
- 2027-12-14
- First posted
- 2024-08-01
- Last updated
- 2026-02-27
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06533644. Inclusion in this directory is not an endorsement.